Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
24 April 2019Website:
http://www.mereobiopharma.comNext earnings report:
06 September 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:22:28 GMTDividend
Analysts recommendations
Institutional Ownership
MREO Latest News
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Depositary Shares (“ADSs”). Each ADS is being sold at a price of $3.99 per ADS in an underwritten registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. Each ADS represents five ordinary shares of Mereo. The net proceeds of this offering are expected to be used to fund the setrusumab program, including supply and pre-launch activities in Europe, and for working capital and other general corporate purposes. The offering is expected to close on or about June 17, 2024, subject to the satisfaction of customary closing conditions.
The intense selling pressure on MEREO BIOPHARMA (MREO) may have subsided as it is currently in oversold territory. Along with this technical indicator, the consensus among analysts on Wall Street raising earnings estimates suggests that the stock is primed for a turnaround.
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.
What type of business is Mereo BioPharma?
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
What sector is Mereo BioPharma in?
Mereo BioPharma is in the Healthcare sector
What industry is Mereo BioPharma in?
Mereo BioPharma is in the Biotechnology industry
What country is Mereo BioPharma from?
Mereo BioPharma is headquartered in United Kingdom
When did Mereo BioPharma go public?
Mereo BioPharma initial public offering (IPO) was on 24 April 2019
What is Mereo BioPharma website?
https://www.mereobiopharma.com
Is Mereo BioPharma in the S&P 500?
No, Mereo BioPharma is not included in the S&P 500 index
Is Mereo BioPharma in the NASDAQ 100?
No, Mereo BioPharma is not included in the NASDAQ 100 index
Is Mereo BioPharma in the Dow Jones?
No, Mereo BioPharma is not included in the Dow Jones index
When does Mereo BioPharma report earnings?
The next expected earnings date for Mereo BioPharma is 06 September 2024